The first end-to-end AI-designed drug wins full FDA approval
TEC-02 · probability 68% (confidence 66%, ±12 pts) over 2026-2030 · horizon NEXT 3-5Y · domain technology. Probabilistic simulation, not advice.
The reading
AlphaFold took the 2024 Nobel in Chemistry, and Insilico's rentosertib — target and molecule both machine-discovered — has already returned positive Phase 2a data. The binding constraint is no longer discovery but trial biology; once one AI-native molecule clears the FDA, the $2.6B-per-drug cost curve starts its terminal decline.
What would prove this wrong
This projection is WRONG if no drug whose target discovery AND molecular design were primarily AI-driven receives FDA approval by end-2030, or AI-discovered candidates fail Phase 3 at rates worse than the historical ~50% baseline.
Trigger events tracked
- Rentosertib-class candidates entering and clearing pivotal Phase 3 trials
- Isomorphic Labs (DeepMind) advancing its first internal candidates to the clinic
- FDA formalizing AI-assisted evidence pathways (building on its own internal AI adoption since 2025)
- A major pharma reporting step-change R&D productivity from AI-first pipelines
Causal chain
Historical precedents
If it happens
Sources
Subjects this belongs to
More on this desk
Browse the Technology & AI desk, the full projection registry, the calibration ledger, or the record by subject. Scoring is explained in how a prediction is made.